Kerendia

News

FDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.

News

Bayer's Kerendia has hit the spot in another phase 3 trial that could fuel its already rapid growth as a chronic kidney disease treatment.

News

Bayer's Kerendia has won FDA approval for a new heart failure indication thought to be pivotal for the product's blockbuster sales prospects.

News

Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.

News

Bayer's CEO says new product launches will offset the decline in sales of anticoagulant Xarelto over the course of 2025.

News

Bayer has filed its mineralocorticoid receptor antagonist finerenone as a treatment heart failure in the EU, but can it meet blockbuster sales hopes?